wire - news in brief

« BACK

Medicine/Pharmacology



Results 1 - 50 of 1313.
1 2 3 4 5 ... 27 Next »

Medicine/Pharmacology - Life Sciences
12.12.2017
Roche announces phase III data showing Venclexta/Venclyxto plus MabThera/Rituxan reduced the risk of disease progression or death by 83% compared to a standard of care regimen in previously treated chronic lymphocytic leukaemia
Roche announces phase III data showing Venclexta/Venclyxto plus MabThera/Rituxan reduced the risk of disease progression or death by 83% compared to a standard of care regimen in previously treated c
Medicine/Pharmacology - Life Sciences
12.12.2017
Medicine/Pharmacology - Life Sciences
11.12.2017
Using 3D cell cultures to fight anti-cancer therapy resistance
Using 3D cell cultures to fight anti-cancer therapy resistance
An international research team headed by the University of Bern and the Netherlands Cancer Institute has developed 3D cell cultures in which genes can be specifically modified. They allow the study of genes that may cause therapy resistance in breast cancer. This knowledge may further improve the use of targeted anti-cancer drugs.
Medicine/Pharmacology - Life Sciences
10.12.2017
Primary analysis results from Novartis pivotal JULIET trial show Kymriah(TM) (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer
Primary analysis results from Novartis pivotal JULIET trial show Kymriah(TM) (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer At six
Medicine/Pharmacology - Innovation/Technology
08.12.2017
Life Sciences - Medicine/Pharmacology
08.12.2017
Acrobatic Duo in the Cells
Acrobatic Duo in the Cells
Just like an acrobatic duo, some proteins lend each other stability. Researchers at the Biozentrum of the University of Basel have discovered that the protein ‘Trigger factor' recognizes a partner by instable, flexible domains, to then together form a stable protein duo. The study has been published in the current issue of ‘Nature Communications'.
Medicine/Pharmacology - Computer Science/Telecom
07.12.2017
Using artificial intelligence to advance personalized medicine
Opened less than a year ago, the Swiss Data Science Center - a joint initiative between EPFL and ETH Zurich - has already launched eight research projects in fields ranging from personalized medicine and environmental protection to open science. Each project brings together experts from several disciplines to join forces in tackling some of society's biggest challenges.
Medicine/Pharmacology - Business/Economics
07.12.2017
Medicine/Pharmacology - Life Sciences
07.12.2017
Phase III IMpower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy reduced the risk of disease worsening or death by 38 percent for people with a type of advanced lung cancer
Phase III IMpower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy reduced the risk of disease worsening or death by 38 percent for people with a type of advanced lung cancer First Phase III combination trial of a cancer immunotherapy to show improvement in progression-free survival as an initial treatment in advanced non-squamous non-small-cell lung cancer (NSCLC) Roche today announced results from the positi
Medicine/Pharmacology
06.12.2017
Novartis Kisqali is first and only CDK4/6 inhibitor to show superior median PFS compared to oral endocrine therapy as first-line treatment in a prospective, randomized Phase III trial dedicated to
Novartis Kisqali is first and only CDK4/6 inhibitor to show superior median PFS compared to oral endocrine therapy as first-line treatment in a prospective, randomized Phase III trial dedicated to..
Medicine/Pharmacology - Administration/Government
06.12.2017
Personalized Health: National Funding for Basel-led Research Groups
Personalized Health: National Funding for Basel-led Research Groups
Nine research projects involving Basel-based researchers in the field of personalized health are to receive funding from the Swiss government: support will be given to researchers from the University
Medicine/Pharmacology - Innovation/Technology
05.12.2017
"The University of Bern is moving briskly ahead"
At the 183rd Dies academicus of the University of Bern, the rector Christian Leumann broached the issue of the freedom of teaching and research, and took stock of the first "half-time" in the university's strategy.
Medicine/Pharmacology - Life Sciences
05.12.2017
Great success for Bern as a medical center
The Swiss Personalized Health Network (SPHN) supports nine research projects with Bernese investment, which aim to build up a nationally coordinated infrastructure of health data.
Medicine/Pharmacology - Law/Forensics
04.12.2017
Medicine/Pharmacology - Innovation/Technology
01.12.2017
Need for Innovation to End Malaria
Need for Innovation to End Malaria
The updated global research agenda for malaria eradication, 'malERA Refresh,' calls for new medicines and tools as well as integrated approaches to address current challenges and ultimately eradicate malaria.
Medicine/Pharmacology - Life Sciences
30.11.2017
Novartis’ Cosentyx is first biologic to show long-term efficacy in nail and palmoplantar psoriasis, which can impact up to 90% of psoriasis patients
Novartis' Cosentyx is first biologic to show long-term efficacy in nail and palmoplantar psoriasis, which can impact up to 90% of psoriasis patients Unique Cosentyx (secukinumab) data reinforce treatment option for up to 90% of psoriasis patients who may develop nail or palmoplantar psoriasis - Cosentyx results represent the first data on biologic use for up to 2.5 years in these hard-to-treat types of psoriasis , Results add to body of e
Medicine/Pharmacology - Life Sciences
29.11.2017
Medicine/Pharmacology - Physics/Materials Science
29.11.2017
Novartis announces Phase III STRIVE data published in NEJM demonstrating significant and sustained efficacy of erenumab in migraine prevention
Novartis announces Phase III STRIVE data published in NEJM demonstrating significant and sustained efficacy of erenumab in migraine prevention Patients with episodic migraine taking erenumab reported
Medicine/Pharmacology
27.11.2017
Novartis’ Ultibro Breezhaler significantly improved COPD patients’ lung function after direct switch from Seretide
New data showed switching moderate-to-severe, symptomatic COPD patients from Seretide * to Ultibro Breezhaler improved lung function and was well tolerated. The FLASH study is the first randomized controlled trial to investigate the direct switch of patients from steroid-containing Seretide to the dual bronchodilator UltibroBreezhaler.
Psychology - Medicine/Pharmacology
27.11.2017
Self-Help Book Works to Combat Burnout and Stress - Without a Therapist
Self-Help Book Works to Combat Burnout and Stress - Without a Therapist
Around a third of all employees find their work stressful. Interventions for stress and burnout are available, but often not accessible for many employees. A self-help book based on Acceptance and Commitment Therapy (ACT) has the potential to reduce burnout, stress and symptoms of depression - without any therapist contact.
Event - Medicine/Pharmacology
22.11.2017
Medicine/Pharmacology - Life Sciences
21.11.2017
Medicine/Pharmacology - Life Sciences
20.11.2017
Novartis drug Tasigna (nilotinib) secures EU approval for first and second-line treatment of Ph+ CML-CP in children
Tasigna is the first and only second-generation tyrosine kinase inhibitor approved in the EU for the treatment of Ph+ CML-CP in children Approval builds on a series of Tasigna regulatory milestones, including addition of Treatment-free Remission (TFR) data to EU label for adults with Ph+ CML-CP Demonstrates Novartis' continuing commitment to CML patients - Novartis announced today that the European Commission (EC) approved Tasigna (nilotinib
Medicine/Pharmacology - Administration/Government
15.11.2017
Novartis, ASCP and ACS join forces to fight cancer in Ethiopia, Uganda and Tanzania
Objective is to provide patients with rapid cancer diagnostics and appropriate care First focus will be on Ethiopia, Uganda and Tanzania Cancer is on the rise in Africa, with more than 500,000 deaths
Medicine/Pharmacology
14.11.2017
Medicine/Pharmacology - Life Sciences
14.11.2017
New data reinforces clinical basis for switching to Sandoz biosimilar medicines
Sandoz strengthens position as global leader in biosimilars with new immunology data from four clinical studies for proposed biosimilars adalimumab and rituximab Efficacy and safety of biosimilar adalimumab and safety of biosimilar rituximab match reference medicines in multiple-switching and retreatment study respectively Sandoz biosimilar adalimumab is under EMA review, while EC-approved Sandoz biosimilar rituximab is under review by the FDA
Medicine/Pharmacology
14.11.2017
Novartis presents new data at SABCS across broad range of breast cancer patient populations, combination treatments and lines of therapy
Presentation of results from the Kisqali (ribociclib) MONALEESA-7 Phase III trial exclusively studying premenopausal women with HR+/HER2- advanced breast cancer New MONALEESA-2 analyses focused on q
Medicine/Pharmacology - Life Sciences
13.11.2017
Novartis canakinumab (ACZ885) reduced cardiovascular risk by 25% in subgroup of CANTOS Phase III trial participants
Subgroup of patients had a 25% reduction in major adverse cardiovascular events when treated with canakinumab in a new analysis of Phase III CANTOS trial presented at the American Heart Association Scientific Sessions 2017   The analysis showed a 31% reduction in cardiovascular death and a 31% reduction in all-cause mortality in patients whose inflammation - as measured by hsCRP - decreased below 2mg/L three months after initiating canakinumab
Medicine/Pharmacology - Life Sciences
13.11.2017
Novartis highlights its differentiated late stage pipeline at the R&D update and investor event
RTH258 demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity and meets primary endpoint of non-inferiority in patients with nAMD   AMG 334 has a robust data package, even in difficult to treat patients, and is on track to be the first CGRP to market for treatment of patients with chronic or episodic migraine   Cosentyx has strong differentiation based on its unique biology, which has been proven to
Medicine/Pharmacology - Social Sciences
12.11.2017
New Novartis Entresto real world evidence data shows beneficial impact on quality of life in people living with heart failure
Entresto reversed trend of worsening New York Heart Association (NYHA) class - a key measure of the severity of a patient's heart failure symptoms - improving common physical activity such as exercise and other daily activities at 90 and 180 days after treatment initiation in a retrospective database study in patients with heart failure with reduced ejection fraction (HFrEF) in Germany Entresto significantly reduced levels of NT-proBNP, a key bl
Medicine/Pharmacology - Administration/Government
11.11.2017
Punjab province in Pakistan signs agreement with Novartis Access against chronic diseases
Poor patients in Punjab will have access to high-quality  medicines against noncommunicable, chronic diseases thanks to agreement between government and Novartis Access Punjab government will make m
Medicine/Pharmacology - Life Sciences
10.11.2017
Use of antibiotics - only if necessary
Bern, 10.11.2017 - Spearheading the fight against antimicrobial resistance, the World Health Organization (WHO) launched its Antibiotic Awareness Week.
Medicine/Pharmacology
10.11.2017
Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness
Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness Brolucizumab, the first and only anti-VEGF to maintain a majority of patients on a 12-week treatment schedule immediately following loading phase in Phase III trials, met primary endpoint of non-inferiority vs aflibercept   Significantly fewer brolucizumab patients showed signs o
Medicine/Pharmacology - Life Sciences
08.11.2017
Novartis reports positive results from Phase III trial of Kisqali (ribociclib) combination therapy in premenopausal women with HR+/HER2- advanced or metastatic breast cancer
Novartis reports positive results from Phase III trial of Kisqali (ribociclib) combination therapy in premenopausal women with HR+/HER2- advanced or metastatic breast cancer MONALEESA-7 met primary e
Medicine/Pharmacology - Life Sciences
07.11.2017
FDA approves Zelboraf (vemurafenib) for Erdheim-Chester disease with BRAF V600 mutation
FDA approves Zelboraf (vemurafenib) for Erdheim-Chester disease with BRAF V600 mutation Zelboraf is the first FDA-approved treatment for Erdheim-Chester disease (ECD), a rare blood disease Approval based on data from a basket study, which enrolls participants across multiple diseases based predominantly on genetic profile Roche announced today that the US Food and Drug Administration (FDA) has approved Zelboraf (vemurafenib) for Erdheim-Chester disease (ECD) with BRAF V600 mutation.
Medicine/Pharmacology
07.11.2017
Novartis announces study data demonstrating Cosentyx reduced signs and symptoms of psoriatic arthritis while inhibiting progression of joint structural damage
Novartis announces study data demonstrating Cosentyx reduced signs and symptoms of psoriatic arthritis while inhibiting progression of joint structural damage Structural joint damage in psoriatic art
Medicine/Pharmacology - Life Sciences
06.11.2017
Novartis reaches another regulatory milestone for CTL019 (tisagenlecleucel) with submission of its MAA* to EMA for children, young adults with r/r B-cell ALL and adult patients with r/r DLBCL
Novartis reaches another regulatory milestone for CTL019 (tisagenlecleucel) with submission of its MAA* to EMA for children, young adults with r/r B-cell ALL and adult patients with r/r DLBCL Applica
Medicine/Pharmacology
06.11.2017
Novartis seeks leadership with Cosentyx showing no radiographic progression in ankylosing spondylitis at 4 years
For the first time for any biologic, data show almost 80 percent of ankylosing spondylitis (AS) patients on Cosentyx have no radiographic progression of the spine at 4 years These new data also confirm sustained improvement in signs and symptoms in almost 80 percent of patients, with a favorable and consistent safety profile Cosentyx, the only IL-17A inhibitor approved for AS, is a fully human, highly targeted biologic for first-line use in this
Life Sciences - Medicine/Pharmacology
03.11.2017
Reading our brain chemistry
Reading our brain chemistry
Researchers at EPFLhave developed a new device and analysis method that let doctors measure the neurochemicals in a patient's brain. The Microsystems Laboratory 4 (LMIS4)'ssystem involves collecting microdroplets of cerebral fluid and analyzing them to obtain chemical data that can help doctors diagnose and treat neurodegenerative diseases.
Life Sciences - Medicine/Pharmacology
02.11.2017
How Caries-Causing Bacteria Can Survive in Dental Plaque
How Caries-Causing Bacteria Can Survive in Dental Plaque
Extracellular polysaccharides play a central role in the survival capabilities of caries-causing bacteria in dental plaque, report researchers from the University of Basel's Preventative Dentistry and Oral Microbiology Clinic and Department of Biomedical Engineering in the journal Plos One. Cariogenic bacteria live in biofilm and attack dental enamel by converting sugar and starch into acids that dissolve out calcium from the enamel.
Medicine/Pharmacology - Life Sciences
02.11.2017
Novartis and Amgen announce expanded collaboration with Banner Alzheimer’s Institute in pioneering prevention program
Parties to collaborate on a new Generation Study 2, assessing whether investigational drug CNP520 can prevent or delay the symptoms of Alzheimer's disease (AD)   Clinical trial is part of the Generation Program, which includes cognitively healthy people at genetic risk of developing AD   Generation Study 2 aims to include a broader high-risk population, as compared to the ongoing Generation Study 1        44 million people globally are e
Medicine/Pharmacology - Administration/Government
01.11.2017
Roche to present new data across a range of blood diseases at the American Society of Hematology (ASH) 2017 Annual Meeting
Roche to present new data across a range of blood diseases at the American Society of Hematology (ASH) 2017 Annual Meeting Further results from emicizumab phase III studies in people with haemophilia
Medicine/Pharmacology - Life Sciences
01.11.2017
Novartis presents data at ASH for patients with serious blood disorders like lymphoma, leukemia and sickle cell disease
Primary results of pivotal Kymriah TM Phase II JULIET study in relapsed/refractory DLBCL Post-hoc sub-analysis of crizanlizumab (SEG101, formerly SelG1) SUSTAIN trial evaluating time to first sickl
Medicine/Pharmacology - Life Sciences
31.10.2017
Novartis submits application to FDA for KymriahTM (tisagenlecleucel) in adult patients with r/r DLBCL, seeking second indication for first-ever FDA approved CAR-T therapy
Novartis submits application to FDA for KymriahTM (tisagenlecleucel) in adult patients with r/r DLBCL, seeking second indication for first-ever FDA approved CAR-T therapy Submission based on updated
Life Sciences - Medicine/Pharmacology
30.10.2017
Important Mechanism of Epigenetic Gene Regulation Identified
DNA contains the blueprint of an entire organism. Based on the information in this blueprint, every cell knows what it must become and what function it must perform. Throughout the entire lifespan of an organism, the genetic information has to be read correctly to ensure that genes are active at the right time and in the right cells.
Medicine/Pharmacology - Business/Economics
30.10.2017
Novartis announces the planned acquisition of Advanced Accelerator Applications to strengthen oncology portfolio
Novartis to acquire Advanced Accelerator Applications pending outcome of tender offer and works council consultation Acquisition would add Lutathera , a first-in-class RadioLigand Therapy (RLT) app
Medicine/Pharmacology
30.10.2017
Novartis to present first of its kind evidence for Cosentyx on potential to maintain mobility in patients with AS and PsA
Long-term 4-year data in ankylosing spondylitis (AS) and 24-weeks data in psoriatic arthritis (PsA) to be presented at the 2017 ACR/ARHP Annual Meeting , Structural disease progression is a major c
1 2 3 4 5 ... 27 Next »